Newer-generation antiseizure medications introduced from the 1990s onward — including levetiracetam, lamotrigine, lacosamide, topiramate, zonisamide, gabapentin, pregabalin, perampanel, brivaracetam, cenobamate, and others — have transformed epilepsy management by offering improved tolerability, fewer interactions, and (in some cases) novel mechanisms. They are now first-line for many patients. This page covers the major newer ASMs, their distinguishing features, and clinical positioning.

Levetiracetam

  • Mechanism: binds SV2A (synaptic vesicle protein); modulates neurotransmitter release.
  • PK: 60% renal clearance; minimal CYP interactions; half-life 6-8 hours.
  • Uses: focal, generalized, myoclonic, mixed seizures; status epilepticus IV (alternative); pregnancy preferred.
  • Side effects: irritability, depression, behavioral changes (especially adolescents); sedation; rare psychiatric effects.
  • Pyridoxine (B6): anecdotal benefit for irritability.
  • “Clean” interaction profile: minimal drug interactions.
  • Renal dose adjustment: substantial reduction in CKD.

Brivaracetam

  • Mechanism: more selective SV2A binding than levetiracetam.
  • PK: hepatic CYP2C19; less renal dependency.
  • Uses: focal seizures; alternative to levetiracetam.
  • Better tolerability: fewer behavioral effects than levetiracetam in some patients.
  • Direct switch from levetiracetam often feasible.

Lamotrigine

  • Mechanism: Na⁺ channel blockade; modulates glutamate release.
  • PK: glucuronidation (UGT1A4); half-life 24 hours; reduced in pregnancy.
  • Uses: focal, generalized tonic-clonic; mood stabilization (bipolar); pregnancy preferred.
  • Side effects: RASH (SJS/TEN) — particularly during titration and with valproate co-administration; sleep disturbance; tic-like movements rarely.
  • Slow titration mandatory: starting 25 mg/day, increasing every 2 weeks; if on valproate, start 12.5 mg/day with even slower titration.
  • Valproate interaction: doubles lamotrigine level → severe rash risk.
  • Pregnancy: clearance increases substantially; dose increase may be needed; postpartum decrease.
  • Avoid in: Dravet syndrome and other Na⁺-channel-sensitive epilepsies (myoclonic worsening).

Topiramate

  • Mechanism: multiple — Na⁺ channels, AMPA/kainate antagonism, GABA enhancement, carbonic anhydrase inhibition.
  • PK: ~70% renal; half-life 21 hours; some CYP3A4 induction at high doses.
  • Uses: focal, generalized tonic-clonic, Lennox-Gastaut; migraine prophylaxis; weight loss (off-label, with phentermine); essential tremor.
  • Side effects: “dopamax” effect (word-finding, slowed thinking, cognitive blunting); weight loss; paresthesias; renal stones; metabolic acidosis; oligohidrosis; secondary angle-closure glaucoma; teratogenic (cleft lip/palate, oral clefts).
  • Slow titration: minimize cognitive effects.
  • OC interaction: reduces ethinyl estradiol levels at higher doses.

Zonisamide

  • Mechanism: Na⁺ channels, T-type Ca²⁺ channels, weak carbonic anhydrase inhibition.
  • PK: hepatic + renal; half-life ~60 hours (once-daily).
  • Uses: focal, generalized; PD (off-label).
  • Side effects: sulfonamide cross-reactivity (rash); cognitive effects; weight loss; renal stones; metabolic acidosis; oligohidrosis (especially children).
  • Avoid in sulfa allergy.

Lacosamide

  • Mechanism: enhances slow inactivation of Na⁺ channels (different from classical Na⁺ blockers).
  • PK: hepatic + renal; half-life 13 hours.
  • Uses: focal seizures; primary generalized tonic-clonic (adjunct); status epilepticus IV.
  • Side effects: dizziness, diplopia, sedation; PR interval prolongation (caution in conduction disease); depression rarely.
  • Combination with other Na⁺ blockers: can be additive.
  • Well-tolerated; minimal interactions.

Perampanel

  • Mechanism: selective non-competitive AMPA receptor antagonist.
  • PK: hepatic CYP3A4; half-life 105 hours (once-daily).
  • Uses: focal seizures (adjunct), primary generalized tonic-clonic.
  • Black box warning: serious psychiatric and behavioral reactions (aggression, hostility, irritability).
  • Other effects: dizziness, sedation.
  • Slow titration: minimize behavioral effects.

Cenobamate

  • Mechanism: Na⁺ channel inactivation enhancement + GABA-A positive modulation.
  • PK: extensive hepatic; half-life ~50 hours.
  • Uses: focal seizures; notable efficacy in pharmacoresistant epilepsy.
  • Side effects: sedation, dizziness; DRESS syndrome (high incidence with rapid titration — VERY slow titration required); cognitive effects.
  • Interactions: CYP3A4 inducer, CYP2C19 inhibitor; affects other ASMs.
  • Increasingly important in refractory focal epilepsy.

Eslicarbazepine

  • Mechanism: Na⁺ channels (similar to carbamazepine).
  • PK: once-daily; half-life ~20 hours.
  • Uses: focal seizures.
  • Side effects: hyponatremia (similar to oxcarbazepine), dizziness, headache.
  • Mild CYP induction.

Gabapentin and Pregabalin

  • Mechanism: bind α2δ subunit of voltage-gated Ca²⁺ channels.
  • PK: gabapentin nonlinear absorption (saturable transporter); pregabalin linear, dose-proportional. Both 100% renal clearance.
  • Uses: focal seizures (adjunct); neuropathic pain (mainstay); restless legs syndrome; generalized anxiety (pregabalin); fibromyalgia; postherpetic neuralgia.
  • Side effects: sedation, dizziness, peripheral edema, weight gain, ataxia.
  • Dose adjustment for renal impairment: substantial reduction.
  • Abuse potential: increasingly recognized, particularly with combined opioid use.
  • Pregabalin schedule V controlled.

Vigabatrin

  • Mechanism: irreversible GABA transaminase inhibitor.
  • Uses: infantile spasms (particularly tuberous sclerosis); refractory focal seizures.
  • Black box warning: progressive permanent visual field defects (constriction).
  • FDA REMS program; ophthalmologic monitoring.
  • Restricted use.

Rufinamide

  • Mechanism: prolongs Na⁺ channel inactive state.
  • Uses: Lennox-Gastaut syndrome.
  • QT shortening (avoid in familial short QT).

Felbamate

  • Mechanism: NMDA antagonism (NR1/2B), GABA modulation, Na⁺ channels.
  • Uses: refractory Lennox-Gastaut; refractory focal.
  • Restricted use: aplastic anemia, hepatic failure — informed consent, monitoring.

Tiagabine

  • Mechanism: GABA reuptake inhibitor (GAT-1).
  • Uses: focal seizures (adjunct).
  • Side effects: dizziness, sedation; non-convulsive status epilepticus in non-epileptic patients (off-label use); rash.
  • Less commonly used.

Cannabidiol (Epidiolex)

  • Mechanism: incompletely understood; multiple targets (GPR55, TRPV1, adenosine, sodium channels).
  • Uses: Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex.
  • Side effects: somnolence, GI, liver enzyme elevation (especially with valproate co-administration), weight loss.
  • Interactions: increases clobazam metabolite levels.
  • NOT same as marketed CBD products (Epidiolex is pharmaceutical-grade, FDA-approved).

Newer/Specialized ASMs

  • Fenfluramine: serotonergic modulator; Dravet syndrome, Lennox-Gastaut.
  • Ganaxolone: neurosteroid; CDKL5 deficiency disorder.
  • Stiripentol: GABA-A allosteric + CYP inhibitor; Dravet (with valproate + clobazam).
  • Soticlestat: investigational; cholesterol-24-hydroxylase inhibitor for Dravet/Lennox-Gastaut.
  • Everolimus: mTOR inhibitor for tuberous sclerosis complex seizures.
  • XEN1101: investigational; potassium channel opener.

Status Epilepticus Pharmacotherapy

  • First-line (5-30 min): IV lorazepam (0.1 mg/kg, max 4 mg/dose), IV diazepam, or IM/buccal/intranasal midazolam.
  • Second-line (10-60 min): IV phenytoin/fosphenytoin, levetiracetam, or valproate.
  • Refractory (after 30-60 min): midazolam infusion, propofol infusion, pentobarbital, ketamine.
  • Newer: lacosamide IV alternative; brivaracetam IV; cenobamate.

🔍 Did You Know?

Cenobamate — approved by the FDA in 2019 — has emerged as one of the most clinically impactful new ASMs in the past two decades, particularly for patients with pharmacoresistant focal epilepsy. In the pivotal trials, approximately 20% of patients achieved seizure freedom at the highest dose — a remarkable response in a population that had typically failed multiple prior ASMs. This level of efficacy in refractory epilepsy was previously rare. The mechanism is dual: enhancement of slow Na⁺ channel inactivation combined with positive allosteric modulation of GABA-A receptors. However, the clinical introduction has required substantial educational efforts because of two challenges: cenobamate has a high risk of DRESS syndrome with rapid titration, requiring very slow uptitration over 11+ weeks; and cenobamate is a significant CYP3A4 inducer and CYP2C19 inhibitor, affecting many other medications including hormonal contraceptives. The lesson generalizes: new ASMs can offer dramatic efficacy gains but require careful prescribing protocols, and the gap between clinical trial efficacy and real-world effectiveness depends on whether clinicians adhere to titration schedules. For neurologists managing pharmacoresistant epilepsy, cenobamate has become an essential tool, but its complexity demands familiarity with the protocol.

Pitfalls and Pearls

  • Levetiracetam: SV2A modulator; “clean”; minimal interactions; renal dose adjustment.
  • Levetiracetam irritability: try pyridoxine; switch to brivaracetam.
  • Lamotrigine titration: very slow; rash risk; even slower with valproate.
  • Lamotrigine pregnancy: clearance increases; monitor levels, increase dose.
  • Topiramate: “dopamax” cognitive effects; renal stones; cleft lip/palate.
  • Zonisamide: sulfa cross-reactivity.
  • Lacosamide: slow Na⁺ inactivation; PR prolongation; well-tolerated.
  • Perampanel: AMPA antagonist; black box behavioral effects.
  • Cenobamate: notable efficacy in refractory focal epilepsy; very slow titration to avoid DRESS.
  • Gabapentin, pregabalin: α2δ ligands; neuropathic pain; renal clearance.
  • Pregabalin schedule V: abuse potential; avoid combining with opioids when possible.
  • Vigabatrin: visual field defects (irreversible); REMS program.
  • Felbamate: aplastic anemia, hepatic failure; informed consent.
  • Cannabidiol (Epidiolex): Dravet, Lennox-Gastaut, TSC; hepatic enzyme elevation with valproate.
  • Status epilepticus first-line: lorazepam/diazepam/midazolam.
  • Second-line: phenytoin/fosphenytoin, levetiracetam, valproate.
  • Refractory: midazolam infusion, propofol, ketamine, pentobarbital.

References

  1. Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy. Neurology. 2018;91(2):74-81.
  2. Chung S, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311-e2322.
  3. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011-2020.
  4. Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults. Epilepsy Curr. 2016;16(1):48-61.
  5. Pellock JM, Brodie MJ, French JA, et al. Felbamate retrospective analysis of aplastic anemia and acute liver failure rates. Epilepsia. 2006;47(12):1942-1952.